Contact us (is on the right)

  1. Company
    1. About
    2. Services
  2. Media
    1. News blog
    2. Meet GCT team
  3. White papers
    1. Region and countries
    2. Therapeutic areas
  4. Services
    1. Site registration
    2. Patient information Center
  5. Website information
    1. Privacy policy
    2. Terms of service
    3. Site map
    4. Employees login

Get in touch

Call us:

Email: info@gctrials.com

Meet us at upcoming industry events

More: Offices, Career at GCT

Patients: Patient information Center

GCT is a CRO contract research organization combining global quality standards with local expertise, teamwork, and professionalism

Phase I-IV clinical trials conducted since 2001

Over 15,000 subjects enrolled

Excellence at enrollment

Projection vs actual enrollment for one of our recent studies

Trusted clinical data

Over 2/3 of all FDA/EMA approved drugs are studied in international trials involving Russia

Shortest regulatory timelines

Our regulatory track is 100% successfull

Headquarters in Princeton, NJ, USA

Six regional offices in CEEcovering Bulgaria, Czech Republic, Hungary, Romania, Russia, Slovakia and Ukraine

Coverage details

Head office, BD office
Princeton, NJ, USA

Phone: 1-609-921-6868
Contact details

Russian office, BD office in St. Petersburg

Phone: 7-812-703-0008
Country information
Contact details

Ukrainian office in Kiev

Phone: 38-044-501-9038
Country information
Contact details

Romanian office in Bucharest

Phone: 40-21-527-0380
Country information
Contact details

Bulgarian office in Sofia

Phone: 359-2-983-5358
Country information
Contact details

Central Europe office in Budapest

Phone: 36-30-353-7538
Hungary information
Czech Republic information
Slovakia information
Contact details

A full-service CRO

We will have you covered end-to-end throughout the trial

  • Study start-up
  • Regulatory services
  • Global, regional, local project management
  • Local safety, medical monitoring support
  • Clinical monitoring
  • Patient recruitment
  • Drug logistics
  • Data management and biostatistics
See a detailed list of our services

In the news

See all news

May 19, 2017

RRMS study close-out meeting

 

GCT is proud to announce that Phase II clinical trial was successfully completed!
Last week Dr. Eugene Selivra, CEO, and Dr. Alexey Vinogradov, Project Manager, visited investigator meeting in Sochi, Russia devoted to the successful Phase II Multiple Sclerosis project completion. During the formal part of the meeting an overview of promising study results was given by the Sponsor and a dynamic discussion on the future application of the study drug took place. After the official part was over, all participants proceeded to a lavish gala-dinner organized by the Sponsor to celebrate project success. Informal and very animated conversations continued, revolving around current standards of care, breakthrough therapies and market potential for the studied product.

April 12, 2017

GCT team completes project training with MAPI Group

As the start-up stage of an observational infant study is actively progressing, our multinational study team has attended a project-specific training held in Budapest by our colleagues from MAPI Group. GCT clinical department members from Russia, Ukraine and Hungary gathered to hold discussions on protocol-specific questions, study timelines and milestones overview, and a round table on enrollment strategies and investigator motivation tools.

The study is a follow up to an international Phase III clinical study in pre-term delivery which GCT is responsible for in CEE countries. The Sponsor for both projects has been our long-term partner, awarding studies to GCT since 2004. We believe this to be a perfect demonstration of the high quality of our work which maintains the trust of our clients for years and makes 80% of our business repeat.

April 11, 2017

Relapsing-Remitting Multiple Sclerosis (RRMS) study completion

GCT Russian team has performed all close-out visits for a double-blind multicenter placebo-controlled study of treatment naïve patients with relapsing-remitting multiple sclerosis. This Phase II study was conducted in Russia with participation of 21 sites which enrolled 227 subjects within 9 months.

For this project GCT provided a full cycle of services: project management, clinical monitoring, regulatory support, drug supply management, local safety reporting, site contracting and payments, central laboratory oversight, data management and statistical analysis.

Meet GCT team

Hear our clients

The management team and the CRAs are physicians, and the lead monitor for our breast cancer trial is an oncologist. The monitoring and reporting of the data are exceptional.

Senior Director, Clinical Operations,
US Pharma